Pharmacologic inhibition of tau phosphorylation at certain key sites that regulate the functional activity of tau or that promote the aggregation of tau in to neurofibrillary tangles may provide a promising approach for the treatment of AD and other tauopathies. This evidence concerns the gene MAPT and tauopathy.